Infantile familial chylomicronemia syndrome caused by LPL gene variants coexisting with renal hamartoma:A case report

Xintao CHEN; Weiyuan FANG; Xiaoyan GONG; Qiong LIN; Yi LU

doi:10.3969/j.issn.1001-5256.2023.04.022

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 896-900

PDF( 2214 KB)

Infantile familial chylomicronemia syndrome caused by LPL gene variants coexisting with renal hamartoma:A case report

DOI: 10.3969/j.issn.1001-5256.2023.04.022

Xintao CHEN^{1a, 2},
Weiyuan FANG^1a,
Xiaoyan GONG^1b,
Qiong LIN²,
Yi LU^{1a
,
,
,}

1a.
The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, Shanghai 201102, China
1b.
Department of Clinical Nutrition, Children's Hospital of Fudan University, Shanghai 201102, China
2.
Department of Gastroenterology, Wuxi Children's Hospital, Wuxi, Jiangsu 214023, China

Research funding:

National Key Research and Development Program of China (2021YFC 2700800)

More Information

Corresponding author: LU Yi, luyi@fudan.edu.cn (ORCID: 0000-0002-3311-4501)
Received Date: 2022-07-30
Accepted Date: 2022-09-13
Published Date: 2023-04-20

Abstract

- Hyperlipoproteinemia Type I,
- Hypertriglyceridemia,
- Renal Hamartoma

FullText(HTML)

References(25)

References

[1]	YANG L, DONG XR, PENG XM, et al. Evaluation of turn around time and diagnostic accuracy of the next generation sequencing data analysis pipeline version 2 of Children's Hospital of Fudan University[J]. Chin J Evid Based Pediatr, 2018, 13(2): 118-123. DOI: 10.3969/j.issn.1673-5501.2018.02.008. 杨琳, 董欣然, 彭小敏, 等. 复旦大学附属儿科医院高通量测序数据分析流程(第二版)对遗传疾病候选变异基因筛选用时和准确性分析[J]. 中国循证儿科杂志, 2018, 13(2): 118-123. DOI: 10.3969/j.issn.1673-5501.2018.02.008
[2]	QIN Q, LIU B, YANG L, et al. Application of copy number variation screening analysis process based on high-throughput sequencing technology[J]. Chin J Evid Based Pediatr, 2018, 13(4): 275-279. DOI: 10.3969/j.issn.1673-5501.2018.04.007. 秦谦, 刘博, 杨琳, 等. 基于高通量测序技术的拷贝数变异筛选分析流程的建立及应用[J]. 中国循证儿科杂志, 2018, 13(4): 275-279. DOI: 10.3969/j.issn.1673-5501.2018.04.007.
[3]	KERSTEN S. Physiological regulation of lipoprotein lipase[J]. Biochim Biophys Acta, 2014, 1841(7): 919-933. DOI: 10.1016/j.bbalip.2014.03.013.
[4]	OLIVECRONA G. Role of lipoprotein lipase in lipid metabolism[J]. Curr Opin Lipidol, 2016, 27(3): 233-241. DOI: 10.1097/MOL.0000000000000297.
[5]	BRAHM A, HEGELE RA. Hypertriglyceridemia[J]. Nutrients, 2013, 5(3): 981-1001. DOI: 10.3390/nu5030981.
[6]	DRON JS, HEGELE RA. Genetics of hypertriglyceridemia[J]. Front Endocrinol (Lausanne), 2020, 11: 455. DOI: 10.3389/fendo.2020.00455.
[7]	FALKO JM. Familial chylomicronemia syndrome: A clinical guide for endocrinologists[J]. Endocr Pract, 2018, 24(8): 756-763. DOI: 10.4158/EP-2018-0157.
[8]	TAKAGI A, IKEDA Y. Genetic diagnosis on hypertriglyceridemia-analysis for LPL gene mutations[J]. Nihon Rinsho, 2013, 71(9): 1569-1576.
[9]	GARG A, GARG V, HEGELE RA, et al. Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 880-886. DOI: 10.1016/S2213-8587(19)30156-1.
[10]	LIU LX, WU YT. Clinical advances in hypertriglyceridemia[J]. Chin J Evidence-Bases Cardiovascular Med, 2020, 12(4): 504-508. DOI: 10.3969/j.issn.1674-4055.2020.04.34. 刘立新, 武云涛. 高甘油三酯血症临床新进展[J]. 中国循证心血管医学杂志, 2020, 12(4): 504-508. DOI: 10.3969/j.issn.1674-4055.2020.04.34.
[11]	CHYZHYK V, BROWN AS. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis[J]. Trends Cardiovasc Med, 2020, 30(2): 80-85. DOI: 10.1016/j.tcm.2019.03.001.
[12]	GALLO A, BÉLIARD S, D'ERASMO L, et al. Familial chylomicronemia syndrome (FCS): recent data on diagnosis and treatment[J]. Curr Atheroscler Rep, 2020, 22(11): 63. DOI: 10.1007/s11883-020-00885-1.
[13]	MOULIN P, DUFOUR R, AVERNA M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score"[J]. Atherosclerosis, 2018, 275: 265-272. DOI: 10.1016/j.atherosclerosis.2018.06.814.
[14]	VALAIYAPATHI B, SUNIL B, ASHRAF AP. Approach to hypertriglyceridemia in the pediatric population[J]. Pediatr Rev, 2017, 38(9): 424-434. DOI: 10.1542/pir.2016-0138.
[15]	CALIÒ A, BRUNELLI M, SEGALA D, et al. Angiomyolipoma of the kidney: from simple hamartoma to complex tumour[J]. Pathology, 2021, 53(1): 129-140. DOI: 10.1016/j.pathol.2020.08.008.
[16]	CHENG L, GU J, EBLE JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas[J]. Am J Surg Pathol, 2001, 25(10): 1231-1236. DOI: 10.1097/00000478-200110000-00002.
[17]	PFIRMANN P, COMBE C, RIGOTHIER C. Tuberous sclerosis complex: A review[J]. Rev Med Interne, 2021, 42(10): 714-721. DOI: 10.1016/j.revmed.2021.03.003.
[18]	CURATOLO P, BOMBARDIERI R, JOZWIAK S. Tuberous sclerosis[J]. Lancet, 2008, 372(9639): 657-668. DOI: 10.1016/S0140-6736(08)61279-9.
[19]	GILBERT B, ROUIS M, GRIGLIO S, et al. Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75% are clustered in exons 5 and 6[J]. Ann Genet, 2001, 44(1): 25-32. DOI: 10.1016/s0003-3995(01)01037-1.
[20]	OKAZAKI H, GOTODA T, OGURA M, et al. Current diagnosis and management of primary chylomicronemia[J]. J Atheroscler Thromb, 2021, 28(9): 883-904. DOI: 10.5551/jat.RV17054.
[21]	STEINHAGEN-THIESSEN E, STROES E, SORAN H, et al. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency[J]. Atherosclerosis, 2017, 262: 146-153. DOI: 10.1016/j.atherosclerosis.2016.08.023.
[22]	WITZTUM JL, GAUDET D, FREEDMAN SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome[J]. N Engl J Med, 2019, 381(6): 531-542. DOI: 10.1056/NEJMoa1715944.
[23]	ELKINS C, FRUH S, JONES L, et al. Clinical practice recommendations for pediatric dyslipidemia[J]. J Pediatr Health Care, 2019, 33(4): 494-504. DOI: 10.1016/j.pedhc.2019.02.009.
[24]	CHAUDHRY R, VILJOEN A, WIERZBICKI AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome[J]. Expert Rev Clin Pharmacol, 2018, 11(6): 589-598. DOI: 10.1080/17512433.2018.1480368.
[25]	MEYERS CD, TREMBLAY K, AMER A, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome[J]. Lipids Health Dis, 2015, 14: 8. DOI: 10.1186/s12944-015-0006-5.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (332) PDF downloads(26)

Infantile familial chylomicronemia syndrome caused by LPL gene variants coexisting with renal hamartoma:A case report

DOI: 10.3969/j.issn.1001-5256.2023.04.022

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Infantile familial chylomicronemia syndrome caused by LPL gene variants coexisting with renal hamartoma:A case report

DOI: 10.3969/j.issn.1001-5256.2023.04.022

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content